文献速递前列腺增生与排尿功能障碍

观点:后网片时代下的尿道吊带

Perspectives on technology: urethral slings in a post-mesh world.
PubMed 文献 · BJU Int · 2024-05-31

本文回顾合成中段尿道吊带(SMUS)与筋膜吊带的疗效、并发症及2011年美国FDA关于经阴道网片安全通告后的实践变化。文献检索EMBASE、PubMed和Cochrane系统评价数据库,纳入2011年后发表的文章。结论认为SMUS争议改变了压力性尿失禁治疗格局,网片产品使用显著减少,但缺乏高质量随机或真实世界登记数据来明确将SMUS排除在治疗算法之外。

要点

  • 2011年FDA安全通告及诉讼使外科医生和患者对网片产品接受度下降。
  • 现有数据难以让患者区分POP与SUI的经阴道网片并发症。
  • 缺乏高质量随机或真实世界登记数据来 definitive 排除SMUS用于SUI治疗。

核心结论

  • SMUS相关争议改变了压力性尿失禁的治疗格局,FDA警告后诉讼背景下合成网片产品使用显著减少。
  • 尽管在严格选择患者中自体筋膜吊带与耻骨后SMUS有充足的手术结局和安全性数据,知情同意和手术培训在新合成材料成熟时至关重要。
  • 由于SMUS仍是SUI的可行选择,「后网片世界」的概念仍有争议。

研究设计与样本

  • 文献检索EMBASE、PubMed和Cochrane系统评价数据库,纳入2011年FDA安全通告后发表的文章。

主要发现

  • 2011年FDA正式安全通告前,经阴道网片(TVM)被视为盆腔器官脱垂(POP)和压力性尿失禁(SUI)的安全治疗选择。
  • 2011年FDA安全通告及随后针对TVM制造商的广泛诉讼改变了外科医生和患者对网片产品的接受度。
  • 已有多个医学和政府机构努力建立监测网片产品手术结局和安全性的方法,如Australasian Pelvic Floor Procedure Registry。
  • SMUS虽具有长期确立的安全性,但SUI网片产品的认知也受到负面影响,其程度尚未通过定性和定量数据充分测量。
  • 现有数据表明患者和消费者难以区分POP与SUI的TVM并发症。

关键数值与推荐

  • 缺乏高质量随机或真实世界登记数据来明确将SMUS排除在SUI治疗算法之外。
  • 在严格选择的患者中,自体筋膜吊带与耻骨后SMUS的手术结局和安全性数据充足。

临床怎么用

  • 作者认为,随着新合成材料达到临床成熟,知情同意和手术培训将至关重要。

局限性

  • SUI网片产品认知负面影响的程度尚未通过定性和定量数据充分测量。
  • 缺乏高质量随机或真实世界登记数据来明确将SMUS排除在SUI治疗算法之外。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To detail the history of synthetic mid-urethral slings (SMUSs) and fascial slings, their efficacy, associated complications, and changes to practice that have occurred after the issuing of the 2011 US Food and Drug Administration (FDA) Safety Communication statement on transvaginal mesh (TVM), and to highlight the need for surgical registries and high-quality randomised controlled data to guide recommendations for continence procedures, in view of current concerns regarding mesh. METHODS: A literature search was conducted in EMBASE, PubMed, and the Cochrane Database of systematic reviews to identify articles published from 2011 onward, following the FDA Safety Communication regarding TVM. RESULTS: Prior to the formal FDA Safety Communication in 2011, TVM was considered a safe option for the treatment of both pelvic organ prolapse (POP) and stress urinary incontinence (SUI). The 2011 FDA safety communications and ensuing widely publicised litigation against TVM manufacturers have shifted both surgeon and patient acceptance of mesh products. Several efforts by medical and government bodies have been made to establish ways to monitor the surgical outcomes and safety of mesh products. The Australasian Pelvic Floor Procedure Registry is one such example. Although SMUSs have a long and established safety profile, perceptions of mesh products for SUI have also been negatively affected. The extent of this, however, has yet to be adequately measured through qualitative and quantitative data. The available data suggest it has been difficult for patients and consumers to distinguish between TVM morbidity for POP vs SUI. Furthermore, there remains a lack of high-quality randomised or real-world registry data to definitively exclude the SMUS from the SUI treatment algorithm. Since SMUSs are a viable option for SUI treatment, the concept of a 'post-mesh world' remains contentious. CONCLUSION: Controversies surrounding SMUSs have changed the treatment landscape of SUI. Against the background of significant litigious action following the FDA warnings against mesh use, there has been significant reduction in the uptake of synthetic mesh products. Although there are ample data related to surgical outcomes and safety for both autologous fascial and retropubic SMUSs in carefully selected patients, informed consent and surgical training will be of paramount importance as newer synthetic materials reach clinical maturity.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Garcia C, Homewood D, Gani J, et al. Perspectives on technology: urethral slings in a post-mesh world. BJU Int. 2024. PMID: 38822540. doi:10.1111/bju.16388

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。